Beyond Glycaemia: Fear of Hypoglycaemia, Cognition and Functional Mobility After Advanced Hybrid Closed-Loop Therapy in Older Adults With Type 1 Diabetes: A Prespecified Secondary Analysis of a Randomised, Single-Centre Study.
Katarzyna Cyranka, Bartłomiej Matejko, Kamila Susuł et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the effects of advanced hybrid closed-loop (AHCL) therapy on psychological and functional outcomes in older adults (≥65 years) with type 1 diabetes. The study found that AHCL therapy was associated with a lower fear of hypoglycaemia score (adjusted mean difference -18.9) and improved performance in mobility-related tests over 12 months, although some findings did not remain statistically significant after adjustments.
Key findings
- AHCL therapy resulted in a lower fear of hypoglycaemia score compared to standard treatment (adjusted mean difference -18.9).
- Participants in the AHCL group showed a significant improvement in 6-minute walk distance (92.6 m).
- Timed Up and Go performance improved significantly in the AHCL group (-2.27 s).
- No significant differences were observed in global cognition or processing speed between groups.
Why it matters
Understanding the psychological and functional impacts of diabetes technologies in older adults is crucial for optimizing diabetes management. This study suggests that AHCL therapy may enhance mobility and reduce fear of hypoglycaemia, potentially improving quality of life in this population.